A quiet revolution in immune cell therapy could reach a critical milestone this spring. According to Mass General Brigham's 2026 predictions, the FDA could approve the first regulatory T cell (Treg) therapy — a treatment designed to prevent graft-versus-host disease (GVHD) in bone marrow transplant recipients.
What Is Graft-Versus-Host Disease?
GVHD is one of the most feared complications of bone marrow transplants. After transplantation, the donor's immune cells can attack the recipient's body, treating it as foreign. The result ranges from skin rashes and digestive problems to life-threatening organ damage.
Current prevention relies on broadly suppressing the immune system with drugs — which works against GVHD but also leaves patients vulnerable to infections and cancers.
The Treg Approach
Regulatory T cells are the immune system's peacekeepers. While other immune cells attack threats, Tregs suppress excessive immune responses and maintain tolerance. The new therapy takes a patient's own Tregs, expands them in the laboratory, and reinfuses them to prevent the donor immune cells from attacking.
The elegance of this approach: it doesn't suppress the entire immune system. Instead, it selectively teaches the transplanted immune cells to coexist with the recipient's body.
Broader Implications
If approved, Treg therapy could extend far beyond transplant medicine. As Live Science reports, researchers are exploring Treg therapies for:
- Autoimmune diseases: Type 1 diabetes, lupus, rheumatoid arthritis
- Organ transplant rejection: Potentially reducing or eliminating the need for lifelong immunosuppressive drugs
- Inflammatory conditions: Crohn's disease, ulcerative colitis
The FDA's decision this spring could open the door to an entirely new category of cell therapies built on immune tolerance rather than immune destruction.
What Regulatory T Cells Do
Regulatory T cells (Tregs) are a specialized subset of immune cells that function as the body's peacekeepers. While most T cells are trained to attack — destroying infected cells, cancer cells, and foreign tissue — Tregs do the opposite: they suppress immune responses to prevent the body from attacking its own healthy tissue.
When this regulatory system malfunctions, the consequences are severe. Autoimmune diseases — conditions where the immune system mistakenly attacks the body — affect approximately 50 million Americans, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, and inflammatory bowel disease. Current treatments typically use broad immunosuppressants that dampen the entire immune system, leaving patients vulnerable to infections and cancer.
The Precision Medicine Approach
The therapy under FDA review, developed by Sonoma Biotherapeutics in collaboration with UCSF, represents a fundamentally different strategy. Rather than suppressing the entire immune system, it expands and engineers a patient's own Tregs to specifically target the autoimmune response while leaving the rest of the immune system intact.
The manufacturing process begins with a blood draw from the patient. Tregs are isolated, expanded to therapeutically relevant numbers (from roughly 50,000 to over 5 billion cells), and in some protocols, engineered with chimeric antigen receptors (CARs) that direct them to specific tissues. The expanded Tregs are then infused back into the patient, where they migrate to sites of inflammation and restore immune tolerance.
Phase 2 clinical data presented at the American College of Rheumatology showed that 67% of type 1 diabetes patients who received the therapy maintained measurable insulin production at 12 months — compared to near-total beta cell destruction in untreated patients. In autoimmune hepatitis, 78% of patients achieved remission without ongoing immunosuppressive drugs.
The Manufacturing Challenge
The biggest obstacle isn't the science — it's the manufacturing. Each Treg therapy is custom-made for an individual patient, requiring sterile cell processing facilities, specialized culture media, and rigorous quality testing. The current cost per treatment is estimated at $250,000–$400,000, comparable to CAR-T cancer therapies.
Sonoma and competitors including Abata Therapeutics (acquired by Eli Lilly for $600M) and GentiBio are investing heavily in manufacturing automation to reduce costs. The long-term vision is to develop "off-the-shelf" allogeneic Treg products from universal donor cells, which could reduce costs by 80% and enable treatment at community hospitals rather than specialized academic centers.
Why This FDA Decision Matters
If approved, the Treg therapy would be the first cell therapy ever authorized for an autoimmune disease. The precedent would be enormous — opening regulatory pathways for similar therapies targeting multiple sclerosis, Crohn's disease, systemic lupus, and organ transplant rejection. It would also signal the FDA's willingness to evaluate living cell therapies using frameworks developed for biologics rather than traditional drugs, potentially accelerating approval timelines for the entire field.
References
Mass General Brigham. (2026). Looking ahead: Predictions for science and medicine in 2026. https://www.massgeneralbrigham.org/en/about/newsroom/articles/2026-predictions-on-scientific-advancements
Live Science. (2026). From gene therapy breakthroughs to preventable disease outbreaks: The health trends that will shape 2026. https://www.livescience.com/health/from-gene-therapy-breakthroughs-to-preventable-disease-outbreaks-the-health-trends-that-will-shape-2026
